Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Preprint]. 2024 Feb 13:2024.02.10.24302621.
doi: 10.1101/2024.02.10.24302621.

Feasibility of Identifying Factors Related to Alzheimer's Disease and Related Dementia in Real-World Data

Aokun Chen  1 , Qian Li  1 , Yu Huang  1 , Yongqiu Li  1 , Yu-Neng Chuang  2 , Xia Hu  2 , Serena Guo  3 , Yonghui Wu  1 , Yi Guo  1 , Jiang Bian  1
Affiliations

Feasibility of Identifying Factors Related to Alzheimer's Disease and Related Dementia in Real-World Data

Aokun Chen et al. medRxiv. .

Abstract

A comprehensive view of factors associated with AD/ADRD will significantly aid in studies to develop new treatments for AD/ADRD and identify high-risk populations and patients for prevention efforts. In our study, we summarized the risk factors for AD/ADRD by reviewing existing meta-analyses and review articles on risk and preventive factors for AD/ADRD. In total, we extracted 477 risk factors in 10 categories from 537 studies. We constructed an interactive knowledge map to disseminate our study results. Most of the risk factors are accessible from structured Electronic Health Records (EHRs), and clinical narratives show promise as information sources. However, evaluating genomic risk factors using RWD remains a challenge, as genetic testing for AD/ADRD is still not a common practice and is poorly documented in both structured and unstructured EHRs. Considering the constantly evolving research on AD/ADRD risk factors, literature mining via NLP methods offers a solution to automatically update our knowledge map.

Keywords: Alzheimer’s Disease and Related Dementia; Natural Language Processing.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
The overall workflow of the study.
Figure 2.
Figure 2.
Our overall literature search and review procedure according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram.
Figure 3.
Figure 3.
An overview of the knowledge graph for AD-related risk factors.
Figure 4.
Figure 4.
Demographic and environmental risk factors for AD: (a) illustrates that age is a risk factor of AD, and (b) illustrates that exposure to pesticide does not have significant effect on AD.
Figure 5.
Figure 5.
Relation between brain trauma and dementia mined from literature via natural language process methods.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. (2023) 2023 Alzheimer’s disease facts and figures. Alzheimers Dement. - PubMed
    1. Lanctôt KL, Rajaram RD, Herrmann N (2009) Therapy for Alzheimer’s Disease: How Effective are Current Treatments? Ther Adv Neurol Disord 2, 163–180. - PMC - PubMed
    1. van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, Froelich L, Katayama S, Sabbagh M, Vellas B, Watson D, Dhadda S, Irizarry M, Kramer LD, Iwatsubo T (2023) Lecanemab in early Alzheimer’s disease. N Engl J Med 388, 9–21. - PubMed
    1. Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, Dent G, Hansson O, Harrison K, von Hehn C, Iwatsubo T, Mallinckrodt C, Mummery CJ, Muralidharan KK, Nestorov I, Nisenbaum L, Rajagovindan R, Skordos L, Tian Y, van Dyck CH, Vellas B, Wu S, Zhu Y, Sandrock A (2022) Two randomized phase 3 studies of aducanumab in early Alzheimer’s disease. J Prev Alzheimers Dis 9, 197–210. - PubMed
    1. Lancet The (2022) Lecanemab for Alzheimer’s disease: tempering hype and hope. Lancet 400, 1899. - PubMed

Publication types